Upstream Bio, Inc.

NASDAQ:UPBHealthcare · Biotechnology

Mkt Cap$150.07M

Float37.92M

Shares O/S54.77M

Inst Own92.2%

Dilution

-8.36%$2.74

AH Close$2.74+0.00%vs close

Mkt Cap$150.07M

Float37.92M

O/S54.77M

Inst Own92.2%

Dilution

NASDAQ:UPB$2.74-8.36%

MCap$150.07M

Float37.92M

O/S54.77M

Inst Own92.2%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$150.07M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership92.22%

based on 54.77M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateOct 11, 2024

Shares Outstanding54.77M

Float37.92M

Company Overview

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system.

Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Leadership

Aaron Deykin, M.D.

Chief Medical Officer and Head of Research and Development

Adam Houghton, Ph.D., M.B.A.

Chief Business Officer

Allison Ambrose, J.D.

Sr. Vice President, General Counsel and Secretary

Daniella Beckman

Director

Employees

Country

Sector

Healthcare

Website

upstreambio.com

Analyst Coverage

ConsensusBuy

Price Target (median, last 90d)

$25.00+812.4%

Low $25High $25

Ratings Distribution

BUY

HOLD

SELL

TOTAL5

Insider Trading

Insider	Title	Type	Shares	Value	Date
Houghton Adam	Chief Business Officer	Sale	700	$3.8K	Sep 16, 2026
Sutherland Everett Rand	Chief Executive Officer	Sale	2.1K	$11.5K	Sep 16, 2026
Deykin Aaron	Chief Medical Officer	Sale	895	$4.9K	Sep 16, 2026
Ambrose Allison	General Counsel	Sale	485	$2.7K	Sep 16, 2026
GRAY MICHAEL	CFO and COO	Sale	853	$4.7K	Sep 16, 2026
GRAY MICHAEL	CFO and COO	Sale	853	$5.2K	Jun 16, 2026

Shareholders

92.2%

Institutional

(149)

1.9%

Insiderⓘ

(6)

22.1%

5%+ Owners

(4)

of which 14.2% rests on schedules older than 24 months (2 holders)

Unattributed (incl. retail)ⓘ

Institutional92.2%

Insider1.9%

5%+ Beneficial22.1%

Top Shareholders

Name	Shares	%	Source
FMR LLC	8.2M	14.9%	13F
FMR LLC · also on 13F· may incl. warrants· filed Feb 2025	7.2M	13.1%	13G
ORBIMED ADVISORS LLC	5.7M	10.4%	13F
AI Upstream LLC 2 · may incl. warrants· stale · filed Oct 2024	5.5M	10.0%	13D
OrbiMed Advisors LLC · also on 13F· may incl. warrants· filed Oct 2024	4.6M	8.3%	13D
NORGES BANK	3.8M	6.9%	13F
BlackRock, Inc.	3.8M	6.9%	13F
Norges Bank · also on 13F· may incl. warrants· filed Oct 2025	2.9M	5.3%	13G
Decheng Capital Global Life Sciences Fund IV, L.P. · also on 13F· joint filing· may incl. warrants· filed May 2026	2.7M	5.0%	13G
Decheng Capital LLC	2.7M	5.0%	13F